WO1997012961B1 - Growth of adult pancreatic islet cells with laminin 5 - Google Patents
Growth of adult pancreatic islet cells with laminin 5Info
- Publication number
- WO1997012961B1 WO1997012961B1 PCT/US1996/015167 US9615167W WO9712961B1 WO 1997012961 B1 WO1997012961 B1 WO 1997012961B1 US 9615167 W US9615167 W US 9615167W WO 9712961 B1 WO9712961 B1 WO 9712961B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iccs
- matrix
- cells
- laminin
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
A method of increasing the number of adult pancreatic islet cells available for transplantation by contacting the cells with laminin 5 extracellular matrix. When contacted with the deposited matrix produced by 804G rat bladder carcinoma cells, a 1,500 fold increase in cell number is observed after three passages in culture. Islet cell expansion also occurs when cells are contacted with 804G soluble matrix. The expanded islet cells contain insulin and respond to glucose challenge.
Claims
1. A method of expanding adult pancreatic islet-like cell clusters (ICCs), comprising the steps of: culturing said ICCs in culture medium in contact with laminin 5; and passaging said cultured ICCs in contact with laminin 5 at least once, whereby the number of said cultured ICCs is significantly increased after said passaging.
2. The method of Claim 1, wherein said larninin 5 is the extracellular matrix produced by 804G or NBT-II rat bladder carcinoma cells.
3. The method of Claim 2, wherein said matrix comprises three polypeptides having molecular weights of about 150 kD, 140 kD, and 135 kD, said matrix characterized as:
(a) promoting enhanced growth of said ICCs in comparison to ICCs grown in the absence of the matrix;
(b) having the ability to promote hemidesmosome formation in epithelial cells cultured thereon;
(c) binding concanavalin; and
(d) being bound by polyclonal antibodies generated against the matrix.
4. The method of Claim 1, wherein said ICCs are from a mammal.
5. The method of Claim 4, wherein said ICCs are from a human.
6. The method of Claim 2, wherein said laminin 5 is deposited by said 804G or said NBT-II cells onto a substrate, said cells are removed from said matrix, and said ICCs are grown in contact with said matrix.
7. The method of Claim 2, wherein said matrix is secreted by said 804G or said NBT-II cells into the culture medium.
8. The method of Claim 7, further comprising purifying said secreted laminin 5 from said culture media.
9. The method of Claim 2, wherein said laminin 5 is produced by 804G cells.
10. The method of Claim 3, wherein said polypeptides are produced from recombinant DNA.
11. The method of Claim 10, wherein said recombinant DNA is human.
12. The method of Claim 1, wherein said laminin 5 is selected from the group consisting of kalinin and epiligrin. -15-
13. The method of Claim 1, wherein said laminin 5 is MCF 10A matrix.
14. The adult pancreatic ICCs prepared in accordance with Claim 1.
15. The method of Claim 1, wherein said ICCs are expanded at least 10 fold.
16. The method of Claim 1, wherein said ICCs are expanded at least 100 fold.
17. The method of Claim 1, wherein said ICCs are passaged at least twice, whereby functional insulin-producing passaged cells are obtained.
18. A method of treating Type I diabetes in a patient in need thereof, comprising the step of administering to said patient an effective insulin-producing amount of the ICCs of Claim 14.
19. The method of Claim 18, wherein said administering step is by implantation under the kidney capsule.
20. The method of Claim 18, wherein said ICCs are placed in an immunoprotective barrier prior to said implantation.
21. The method of Claim 18, wherein said administering step is by direct injection into the liver.
22. The method of Claim 18, wherein said effective insulin-producing amount is between about 2 x 105 and about 8 x 105 ICCs.
23. An effective insulin-producing amount of the ICCs of Claim 14 for use in treatment of Type I diabetes.
24. The ICCs of Claim 23, wherein said ICCs are human.
25. Use of the ICCs of Claim 14 in the preparation of a medicament for treatment of Type I diabetes.
26. The use of Claim 25, wherein said ICCs are human.
- 1 6-
STATEMENT UNDER ARTICLE 19
The claims have been amended to recite that adult ICCs are passaged at least once in culture. The cited references disclose growth, not passaging, of adult pancreatic islet cells on 804G matrix and other extracellular matrices. In view of the claim amendments, favorable international preliminary examination is respectfully requested.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9514294A JPH11513253A (en) | 1995-10-06 | 1996-09-23 | Growth of adult islet cells by laminin-5 |
| EP96935891A EP0859830B1 (en) | 1995-10-06 | 1996-09-23 | Growth of adult pancreatic islet cells with laminin 5 |
| DE69630972T DE69630972T2 (en) | 1995-10-06 | 1996-09-23 | GROWTH OF ADULTS PANCREAS LANGENHANS CELLS WITH LAMININ-5 |
| AT96935891T ATE255631T1 (en) | 1995-10-06 | 1996-09-23 | GROWTH OF ADULT PANCREAS LANGENHANS CELLS WITH LAMININ-5 |
| AU73672/96A AU706581B2 (en) | 1995-10-06 | 1996-09-23 | Growth of adult pancreatic islet cells |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US487895P | 1995-10-06 | 1995-10-06 | |
| US08/626,394 | 1996-03-29 | ||
| US08/626,394 US5681587A (en) | 1995-10-06 | 1996-03-29 | Growth of adult pancreatic islet cells |
| US60/004,878 | 1996-03-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1997012961A2 WO1997012961A2 (en) | 1997-04-10 |
| WO1997012961A3 WO1997012961A3 (en) | 1997-05-22 |
| WO1997012961B1 true WO1997012961B1 (en) | 1997-07-10 |
Family
ID=26673609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/015167 Ceased WO1997012961A2 (en) | 1995-10-06 | 1996-09-23 | Growth of adult pancreatic islet cells with laminin 5 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5681587A (en) |
| EP (1) | EP0859830B1 (en) |
| JP (1) | JPH11513253A (en) |
| AT (1) | ATE255631T1 (en) |
| AU (1) | AU706581B2 (en) |
| CA (1) | CA2233859A1 (en) |
| DE (1) | DE69630972T2 (en) |
| ES (1) | ES2211988T3 (en) |
| WO (1) | WO1997012961A2 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231881B1 (en) | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
| US6352707B1 (en) | 1992-02-24 | 2002-03-05 | Anton-Lewis Usala | Transplant encapsulation in a hydrogel matrix to obscure immune recognition |
| USRE36844E (en) * | 1993-04-05 | 2000-08-29 | Desmos Incorporated | Cellular attachment to trans-epithelial appliances |
| US5672361A (en) * | 1996-03-29 | 1997-09-30 | Desmos, Inc. | Laminin 5 for growth of pancreatic islet cells |
| US6294356B1 (en) | 1998-01-16 | 2001-09-25 | Northwestern University | Methods and materials for making and using laminin-5 |
| AU3572299A (en) * | 1998-04-22 | 1999-11-08 | Desmos, Inc. | Creation of bioactive surfaces through selective adsorption |
| EP1080183A1 (en) * | 1998-05-29 | 2001-03-07 | Desmos, Inc. | Promotion of cell differentiation by initially passaged cells |
| EP1383530A4 (en) * | 1998-10-13 | 2004-04-28 | Gen Hospital Corp | Laminin 5, 13 and 14 and uses thereof |
| US6242666B1 (en) | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
| JP2002535982A (en) * | 1999-02-04 | 2002-10-29 | マックギル ユニヴァーシティー | Platform for cell differentiation |
| US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
| US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
| WO2000066731A2 (en) * | 1999-04-30 | 2000-11-09 | Biostatum, Inc. | Recombinant laminin 5 |
| AU4678400A (en) | 1999-04-30 | 2000-11-17 | Biostratum, Inc. | Laminin 8 and methods for its use |
| EP1173568A2 (en) | 1999-04-30 | 2002-01-23 | University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School | Laminin 2 and methods for its use |
| US6703363B1 (en) * | 1999-04-30 | 2004-03-09 | Biostratum, Inc. | Recombinant laminin 5 |
| EP1185622A4 (en) * | 1999-06-23 | 2002-09-18 | Joslin Diabetes Center Inc | Process for the production of pancreatic islet cells |
| US6815203B1 (en) * | 1999-06-23 | 2004-11-09 | Joslin Diabetes Center, Inc. | Methods of making pancreatic islet cells |
| CA2385628A1 (en) * | 1999-09-27 | 2001-04-05 | Ammon B. Peck | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| EP1265985A4 (en) * | 2000-02-18 | 2004-06-23 | Inst Medical W & E Hall | GROWTH FACTORS OF INSULIN-SECRECTIVE PANCREATIC CELLS |
| US8039254B2 (en) * | 2004-11-22 | 2011-10-18 | Ramot At Tel-Aviv University Ltd. | Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same |
| US20080103606A1 (en) * | 2006-10-30 | 2008-05-01 | Cory Berkland | Templated islet cells and small islet cell clusters for diabetes treatment |
| US8735154B2 (en) * | 2006-10-30 | 2014-05-27 | The University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| US8895048B2 (en) * | 2010-04-06 | 2014-11-25 | The University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| JP6177687B2 (en) * | 2010-05-07 | 2017-08-09 | ユニバーシティー オブ ノース カロライナ アット チャペル ヒル | Use of a mixture used in the manufacture of a medicament for transplantation of cells from parenchyma |
| KR101327630B1 (en) * | 2012-03-05 | 2013-11-13 | 울산대학교 산학협력단 | Method for manufacturing a carrier of transplanting pancreatic islet cells using atelocollagen, and artificial pancreas manufactured by the same method |
| WO2019098944A1 (en) * | 2017-11-15 | 2019-05-23 | National University Of Singapore | Systems for expanding pancreatic islets and transplantation thereof |
| CN113308433A (en) * | 2021-04-27 | 2021-08-27 | 立沃生物科技（深圳）有限公司 | Method for treating hybrid cells on surface of islet in-vitro culture |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU663083B2 (en) * | 1991-03-26 | 1995-09-28 | State of Oregon acting by and through The State Board of Higher Education on behalf of The Oregon Health Sciences University, The | Product and method for improving keratinocyte adhesion to the dermis |
| JPH08502733A (en) * | 1992-08-28 | 1996-03-26 | オレゴン州 | Products and methods for improving adhesion of keratinocytes to the dermis |
| US5422264A (en) * | 1993-11-12 | 1995-06-06 | Desmos, Inc. | Soluble factor stimulation of attachment and hemidesmosome assembly in epithelial cells |
| US5510263A (en) * | 1993-04-05 | 1996-04-23 | Desmos, Inc. | Growth of pancreatic islet-like cell clusters |
| US5541106A (en) * | 1993-04-05 | 1996-07-30 | Desmos, Inc. | Cell matrix stimulated attachment and hemidesmosome assembly |
| EP1808439A3 (en) * | 1993-09-02 | 2008-03-12 | Fred Hutchinson Cancer Research Center | Epiligrin, an epithelial ligand for integrins |
| US5834308A (en) * | 1994-04-28 | 1998-11-10 | University Of Florida Research Foundation, Inc. | In vitro growth of functional islets of Langerhans |
-
1996
- 1996-03-29 US US08/626,394 patent/US5681587A/en not_active Expired - Fee Related
- 1996-09-23 ES ES96935891T patent/ES2211988T3/en not_active Expired - Lifetime
- 1996-09-23 JP JP9514294A patent/JPH11513253A/en not_active Ceased
- 1996-09-23 AT AT96935891T patent/ATE255631T1/en not_active IP Right Cessation
- 1996-09-23 WO PCT/US1996/015167 patent/WO1997012961A2/en not_active Ceased
- 1996-09-23 CA CA002233859A patent/CA2233859A1/en not_active Abandoned
- 1996-09-23 DE DE69630972T patent/DE69630972T2/en not_active Expired - Fee Related
- 1996-09-23 EP EP96935891A patent/EP0859830B1/en not_active Expired - Lifetime
- 1996-09-23 AU AU73672/96A patent/AU706581B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997012961B1 (en) | Growth of adult pancreatic islet cells with laminin 5 | |
| EP1312669B1 (en) | Cultured epidermal cell sheet, laminated cultured skin sheet and process for producing the same | |
| US5827853A (en) | Cosmetic composition containing a neuropeptide Y receptor antagonist | |
| EP1666585B1 (en) | Macroencapsulated secretory cells | |
| JP2004506598A5 (en) | ||
| WO1997012961A3 (en) | Growth of adult pancreatic islet cells with laminin 5 | |
| KR880700854A (en) | New Fixed Biocatalysts and Their Preparation and Uses | |
| US20120210451A1 (en) | Islet cell sheet, process for production thereof, and use thereof | |
| JPS6133593B2 (en) | ||
| JPH11507227A (en) | Bile duct progenitor cells and methods of use | |
| RU2003121231A (en) | SILENT ANTI-CD28 ANTIBODIES AND THEIR APPLICATION | |
| Wells et al. | Microencapsulation of viable hepatocytes in HEMA-MMA microcapsules: a preliminary study | |
| CA2272130A1 (en) | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) | |
| CA2269096A1 (en) | Method for in vitro preconditioning of myoblasts before transplantation | |
| Miyoshi et al. | Histological analysis of microencapsulated dopamine-secreting cells in agarose/poly (styrene sulfonic acid) mixed gel xenotransplanted into the brain | |
| Akaike et al. | Separation of parenchymal liver cells using a lactose-substituted styrene polymer substratum | |
| KR101761092B1 (en) | Composition for Transplanting of Islet Cells | |
| Dixit et al. | Repeated transplantation of microencapsulated hepatocytes for sustained correction of hyperbilirubinemia in Gunn rats | |
| Zekorn et al. | Islet transplantation in immunoseparating membranes for treatment of insulin-dependent diabetes mellitus | |
| JP5224440B2 (en) | Three-dimensional cultured elastic fiber tissue and method for producing three-dimensional cultured elastic fiber tissue | |
| WO2019098944A1 (en) | Systems for expanding pancreatic islets and transplantation thereof | |
| Lelli et al. | Preparation and characterization of permselective, biocompatible membranes for the macroencapsulation of pancreatic islets | |
| CN115948322B (en) | A method for culturing cells using a monolayer of self-assembling polypeptide solution | |
| WO2001079453A1 (en) | Cell culture method, cell cluster obtained by said methods and use thereof | |
| Tsujita et al. | Evidence for the presence of membrane-bound forms of acid protease in Aspergillus oryzae |